Hypoxia may be a determinative factor in COVID-19 progression

The disease which develops following SARS-CoV-2 virus infection, known as COVID-19, in most affected countries displays mortality from 1.5% to 9.8%. When leukocytosis due to granulocytosis, thrombocytopenia, and increased level of D-dimers are detected early during the disease course, they are accur...

Descripción completa

Detalles Bibliográficos
Autores principales: Grieb, Pawel, Swiatkiewicz, Maciej, Prus, Katarzyna, Rejdak, Konrad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
COVID-19 therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106824/
https://www.ncbi.nlm.nih.gov/pubmed/34870146
http://dx.doi.org/10.1016/j.crphar.2021.100030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106824/
https://www.ncbi.nlm.nih.gov/pubmed/34870146
http://dx.doi.org/10.1016/j.crphar.2021.100030

Ejemplares similares